North America Pharmacokinetics and Pharmacodynamics Market to Grow at a CAGR of 7.09% During 2025 to 2035; Driven by Increasing Demand for Advanced Drug Development and Personalized Medicine

North America Pharmacokinetics Pharmacodynamics Market Highlights

North America Pharmacokinetics and Pharmacodynamics Market was estimated at 0.7496 USD Billion in 2024. The market is projected to grow from 0.8028 USD Billion in 2025 to 1.593 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 7.09% during the forecast period 2025 - 2035

MRFR recognizes the following companies as the key players in the North America Pharmacokinetics and Pharmacodynamics market — LGC Limited, Eurofins Scientific, Creative Biolabs, Creative Bioarray, Quanticate, Pacific BioLabs, Inc., Allucent, Charles River Laboratories, Evotec AG, SGS Société Générale de Surveillance SA. and others.

The growth of the North America pharmacokinetics and pharmacodynamics market is attributed to the increasing prevalence of chronic diseases, advancements in technology and analytical techniques, and strong healthcare infrastructure. For instance, as per the National Cancer Institute, an estimated 1,806,590 new cancer cases were diagnosed in the US in 2020. Similarly, according to the US Department of Health and Human Services, the prevalence of cancer in the US is 439.2 per 100,000 men and women.

Segment Analysis

Based on service type, the North America pharmacokinetics and pharmacodynamics market has been segmented into pharmacokinetic services, and pharmacodynamic services. The pharmacokinetic services segment is further segmented into drug absorption studies, drug distribution studies, drug metabolism studies, drug excretion studies, and others. pharmacodynamic services further segmented into receptor binding studies, biomarker analysis, and others.

Based on drug type, the North America pharmacokinetics and pharmacodynamics market is bifurcated into small molecules and large molecules.

Based on therapeutic area, the North America pharmacokinetics and pharmacodynamics market has been segmented into oncology, cardiovascular, infectious disease, neurology, immunology, and others.

Based on end user, the North America pharmacokinetics and pharmacodynamics market has been segmented into pharmaceutical and biotechnology companies, academic and research institutions, and others.

Regional Analysis

The North America pharmacokinetics and pharmacodynamics market is segmented into the US and Canada. The US held the largest market share of 82.34% based on region and Canada is anticipated to dominate the overall pharmacokinetics and pharmacodynamics market during the forecast period.

Key Findings of the Study

• The market is increasingly leaning towards personalized medicine, enhancing treatment efficacy and patient outcomes.


• Technological integration is transforming drug development processes, particularly in pharmacokinetic services, which remain the largest segment.


• Collaborative research efforts are gaining momentum, especially between North America and the rapidly growing Asia-Pacific region.


• Rising demand for personalized medicine and advancements in drug development technologies are key drivers propelling market expansion.